Clinical Trial Goal
To find out:
- The highest dose of CLN-049 that's safe to give
- If CLN-049 is safe and works well to treat AML that has relapsed or is refractory or MDS
You may be able to join this trial if you:
- Are 18 years or older
- Have one of the following:
- AML that has relapsed or is refractory
- MDS
- Have not been treated with CAR T-cell therapy
- Have not been treated with a drug that targets FLT3
- Have not had allogeneic (cells from a donor) blood or marrow transplant (BMT) in the last 6 months
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
CLN-049 is a bispecific T-cell engager (BiTE) antibody that targets FLT3 on certain cells.
You’ll get treatment in cycles that last 1 month. In each cycle, you'll get:
You’ll get treatment in cycles that last 1 month. In each cycle, you'll get:
- CLN-049 – Given as intravenous (IV) infusions or as a shot under your skin up to 1 time each week
You'll have biopsies to see how well the treatment is working. The clinical trial doctors will check your health for up to 2 years.
The Food and Drug Administration (FDA) has not yet approved CLN-049.
Locations
Sponsors
lead: Cullinan Therapeutics Inc.
